Research field (2)：
Tumor biology
, Respiratory medicine
Research keywords (6)：
respiratory medicine
, oxidative response system
, personalized medicine
, genome biology
, molecular biology
, lung cancer
Research theme for competitive and other funds (4)：
2023 - 2026 肺癌における酸化ストレス応答系の新規破綻機序の解明と標的治療の探索
2021 - 2025 中皮腫における細胞系譜構築による新規治療法の探究と臨床応用
2020 - 2023 小細胞肺癌における酸化ストレス応答系の破綻機序の解明
2013 - 2015 非小細胞肺癌を標的とするNrf2阻害剤の開発
Papers (52)：
Monami Kishi, Takuo Hayashi, Keiko Mitani, Kenji Tsuboshima, Masatoshi Kurihara, Masaki Hosoya, Yasuhito Sekimoto, Makiko K Okura, Yoichiro Mitsuishi, Yoshinori Okada, et al. Clinicopathological Impacts of Expression of Neuronal Markers in Lymphangioleiomyomatosis. The American journal of surgical pathology. 2023. 47. 11. 1252-1260
Koichiro Kanamori, Kentaro Suina, Takehito Shukuya, Fumiyuki Takahashi, Takuo Hayashi, Kieko Hara, Tsuyoshi Saito, Yoichiro Mitsuishi, Shoko Sonobe Shimamura, Wira Winardi, et al. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma. Thoracic cancer. 2023. 14. 12. 1089-1097
Shiting Xu, Keita Miura, Takehito Shukuya, Sonoko Harada, Masahiro Fujioka, Wira Winardi, Shoko Shimamura, Kana Kurokawa, Issei Sumiyoshi, Taichi Miyawaki, et al. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines. Cancers. 2023. 15. 4
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Naoaki Ito, Misa Ogiwara, Keita Miura, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, et al. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer. Thoracic cancer. 2022. 14. 5. 442-449
Kana Kurokawa, Yoichiro Mitsuishi, Naoko Shimada, Yuta Kawakami, Keita Miura, Taichi Miyawaki, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Rina Shibayama, et al. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC cancer. 2022. 22. 1. 1047-1047
